Nyxoah (NYXH) Total Debt to Capital

Nyxoah S.A. (NYXH) neurostimulator production is based at facilities in the US and Belgium, where strict controls are maintained over cleanroom standards and chip availability. The historical price dynamics of total debt-to-equity stand at 0.74. The company successfully retains its R&D staff while simultaneously hiring sales managers for Western markets. Financial stability remains weak due to the launch of apnea therapy and a reliance on insurance reimbursements.

The ratio is calculated as total liabilities divided by net equity, reflecting the balance sheet's sensitivity to external borrowings. This metric determines the degree of financial autonomy and the risk of asset impairment in the event of declining revenues. For Nyxoah S.A. (NYXH), which is scaling neurostimulator sales through insurance systems, a margin of safety is critically important. The current value of 0.74 characterizes the level of credit leverage. By analyzing the dynamics of the debt dependency ratio, an investor assesses the sustainability of the business model.